The liver in pediatric gastrointestinal disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 59, Issue 3, 2014, Pages 288-299

  Vo, Hanh D ^a   Xu, Jiliu ^a   Rabinowitz, Simon S ^a   Fisher, Stanley E ^a   Schwarz, Steven M ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; CHOLAGOGUE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

CANCER RISK; CANCER SCREENING; CELIAC DISEASE; CLINICAL FEATURE; CYSTIC FIBROSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL DISEASE; GENETIC ANALYSIS; HEPATOBILIARY DISEASE; HUMAN; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; LIVER DISEASE; LIVER TOXICITY; MESENTERY BLOOD VESSEL; PATHOGENESIS; PORTAL VEIN; PRIORITY JOURNAL; REVIEW; TOXIC HEPATITIS; VASCULARIZATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CHILD; CHOLANGITIS, SCLEROSING; COMPLICATION; DIET THERAPY; DRUG-INDUCED LIVER INJURY; INFANT; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; LIVER FUNCTION TEST; PRESCHOOL CHILD;

6-MERCAPTOPURINE; ADOLESCENT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CELIAC DISEASE; CHILD; CHILD, PRESCHOOL; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; CYSTIC FIBROSIS; DRUG-INDUCED LIVER INJURY; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; LIVER FUNCTION TESTS; METHOTREXATE; TUMOR NECROSIS FACTOR-ALPHA; URSODEOXYCHOLIC ACID;

EID: 84907330375     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000444     Document Type: Review

References (206)

1. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1598-619.
2. Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007;102:344-50.
3. Loftus EV Jr, Sandborn WJ, Lindor KD, et al. Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis 1997;3:288-302.
4. Hyams J, Markowitz J, Treem W, et al. Characterization of hepatic abnormalities in children with inflammatory bowel disease. Inflamm Bowel Dis 1995;1:27-33.
5. Nemeth A, Ejderhamn J, Glaumann H, et al. Liver damage in juvenile inflammatory bowel disease. Liver 1990;10:239-48.
6. Memon MI, Memon B, Memon MA. Hepatobiliary manifestations of inflammatory bowel disease. HPB Surg 2000;11:363-71.
7. Nahon S, Cadranel JF, Chazouilleres O, et al. Liver and inflammatory bowel disease. Gastroenterol Clin Biol 2009;33:370-81.
8. McCluggage WG, Sloan JM. Hepatic granulomas in Northern Ireland: a thirteen year review. Histopathology 1994;25:219-28.
9. Veloso FT, Dias LM, Carvalho J, et al. Ulcerative colitis, primary biliary cirrhosis, and chronic pancreatitis: coincident or coexistent? J Clin Gastroenterol 1993;16:55-7.
10. Lever E, Balasubramanian K, Condon S, et al. Primary biliary cirrhosis associated with ulcerative colitis. Am J Gastroenterol 1993;88:945-7.
11. Singh S, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol 2013;11:898-907.
12. Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cho-langitis. Best Pract Res Clin Gastroenterol 2001;15:553-62.
13. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103.
14. Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007;102:1042-9.
15. Jorgensen KK, Grzyb K, Lundin K E A, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012;18:536-45.
16. Floreani A, Zancan L, Melis A, et al. Primary sclerosing cholangitis (PSC): clinical, laboratory and survival analysis in children and adults. Liver 1999;19:228-33.
17. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7.
18. Faubion WA, Loftus EV, Sandborn WJ, et al. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J Pediatr Gastroenterol Nutr 2001;33:296-300.
19. Batres LA, Russo P, Mathews M, et al. Primary sclerosing cholangitis in children: a histologic follow-up study. Pediatr Dev Pathol 2005;8:568-76.
20. Miloh T, Arnon R, Shneider B, et al. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroen-terol Hepatol 2009;7:239-45.
21. Feldstein AE, Perrault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210-7.
22. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-53.
23. Wilschanski M, Chait P, Wade JA, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features with survival analysis. Hepatology 1995;22:1415-22.
24. El-Shabrawi M, Wilkinson ML, Portmann B, et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987;92:1226-35.
25. Sisto A, Feldman P, Garel L, et al. Primary sclerosing cholangitis in children: study of five cases and review of the literature. Pediatrics 1987;80:918-23.
26. Debray D, Pariente D, Urvoas E, et al. Sclerosing cholangitis in children. J Pediatr 1994;124:49-56.
27. La Russo NF, Shneider BL, Black D, et al. Primary sclerosing cho-langitis: summary of a workshop. Hepatology 2006;44:746-64.
28. Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 2010;51:140-5.
29. Ong JC, O'Loughlin EV, Kamath KR, et al. Sclerosing cholangitis in children with inflammatory bowel disease. Aust N Z J Med 1994;24:149-53.
30. Alexopoulou E, Xenophontos PE, Economopoulos N, et al. Investigative MRI cholangiopancreatography for primary sclerosing cholan-gitis-type lesions in children with IBD. J Pediatr Gastroenterol Nutr 2012;55:308-13.
31. Ibrahim SH, Lindor KD. Current management of primary sclerosing cholangitis in pediatric patients. Pediatr Drugs 2011;13:87-95.
32. Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastro-enterol Hepatol 2008;6:939-43.
33. Neri TM, Cavestro GM, Seghini P, et al. Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population. Dig Liver Dis 2003;35:571-6.
34. Jose FA, Heyman MB, Ferrell L, et al. Clinical course of pediatric patients with primary sclerosing cholangitis. Gastroenterology 2009;136:A505-6.
35. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364-9.
36. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004;126:1929-30.
37. Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009;33:854-62.
38. Loftus EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-6.
39. Hyams JS, Davis P, Grancher K, et al. Clinical outcome of ulcerative colitis in children. J Pediatr 1996;129:81-8.
40. Mieli-Vergani G, Vergani D. Unique features of primary sclerosing cholangitis in children. Curr Opin Gastroenterol 2010;26:265-8.
41. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005;100:1516-22.
42. Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary scleros-ing cholangitis. World J Gastroenterol 2008;14:3781-91.
43. Cullen SN, Chapman RW. Current management of primary sclerosing cholangitis [review article]. Aliment Pharmacol Ther 2005;21:933-48.
44. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78.
45. Dave M, Elmunzer BJ, Dwamena BA, et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholan-giopancreatography. Radiology 2010;256:387-96.
46. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenter-ology 2001;121:900-7.
47. Stiehl A, Walker S, Stiehl L, et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994;20:57-64.
48. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeo-xycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14.
49. Chen W, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2003;2: CD003626.
50. Davies YK, Cox KM, Abdullah BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008;47:61-7.
51. Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study. Aliment Pharmacol Ther 2013;37:604-12.
52. Silveira MG, Torok NJ, Gossard AA, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009;104:83-8.
53. Boner AL, Peroni D, Bodini A, et al. Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int J Immunopathol Pharmacol 2007;20:847-9.
54. Farkkila M, Karvonen AL, Nurmi H, et al. Metronidazole and urso-deoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40:1379-86.
55. Angulo P, Batts KP, Jorgensen RA, et al. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2333-7.
56. Lindor KD, Jorgensen RA, Anderson ML, et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 1996;91:511-5.
57. Talwalkar JA, Angulo P, Keach JC, et al. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005;100:308-12.
58. Talwalkar JA, Gossard AA, Keach JC, et al. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007;27:451-3.
59. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cho-langitis. Hepatology 1999;30:1121-7.
60. Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004;99:538-42.
61. Miloh T, Anand R, Yin W, et al. Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl 2011;17:925-33.
62. Navaneethan U, Venkatesh PG, Mukewar S, et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:540-6.
63. Marelli L, Xirouchakis E, Kalambokis G, et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011;60:1224-8.
64. Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver 2000;20:97-103.
65. Papatheodoridis GV, Hamilton M, Mistry PK, et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998;43:639-44.
66. Papatheodoridis GV, Hamilton M, Rolles K, et al. Liver transplantation and inflammatory bowel disease. J Hepatol 1998;28:1070-6.
67. Ho GT, Seddon AJ, Therapondos G, et al. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol 2005;17:1379-85.
68. Singh S, Loftus EV Jr, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol 2013;108:1417-25.
69. Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009;15:330-40.
70. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54.
71. Claessen MM, Lutgens MW, Van Buuren HR, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009;15:1331-6.
72. Torres J, Pineton De Chambrun G, Itzkowitz S, et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:497-508.
73. Kerkar N, Miloh T. Sclerosing cholangitis: pediatric perspective. Curr Gastroenterol Rep 2010;12:195-202.
74. Ross AM, Anupindi SA, Balis UJ. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 11-2003. A 14-year-old boy with ulcerative colitis, primary sclerosing cholangitis, and partial duodenal obstruction. N Engl J Med 2003;348:1464-76.
75. Charatcharoenwitthaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008;48:1106-17.
76. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006;131:1064-72.
77. Levy C, Lymp J, Angulo P, et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005;50:1734-40.
78. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14:325-31.
79. Smyth C, Kelleher D, Keeling PW. Hepatic manifestations of gastrointestinal diseases. Inflammatory bowel disease, celiac disease, and Whipple's disease. Clin Liver Dis 2002;6:1013-32.
80. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercapto-purine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42.
81. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003;125:298-303.
82. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007;102:1518-27.
83. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007;56:1404-9.
84. Daniel F, Cadranel JF, Seksik P, et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol 2005;29:600-3.
85. Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;22:775-82.
86. Qasim A, Seery J, Buckley M, et al. TPMT in the treatment of inflammatory bowel disease with azathioprine. Gut 2003;52:767.
87. Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2:1273-6.
88. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
89. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mer-captopurine (6-MP) and azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 2007;102:2488-94.
90. Bashir RM, Lewis JH. Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders. Gastroenterol Clin North Am 1995;24:937-67.
91. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyper-plasia: not all nodules are created equal. Hepatology 2006;44:7-14.
92. Geller SA, Dubinsky MC, Poordad FF, et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 2004;28:1204-11.
93. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005;43:303-9.
94. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of metho-trexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
95. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203-9.
96. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000;95:1730-4.
97. Fournier MR, Klein J, Minuk GY, et al. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gas-troenterol 2010;105:1620-6.
98. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral metho-trexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001;15:35-44.
99. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
100. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
101. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;95:3150-6.
102. Domenech E, Manosa M, Navarro M, et al. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J Clin Gastroenterol 2008;42:395-9.
103. Khan N, Abbas AM, Whang N, et al. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis 2012;18:359-67.
104. Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol 2010;24:157-65.
105. Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:693-7.
106. Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis:2009 National Psoriasis Foundation Consensus Conference. JAm Acad Dermatol 2009;60:824-37.
107. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance inflix-imab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
108. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
109. Efe C. Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship? Autoimmun Rev 2013;12:337-9.
110. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001;76:84-6.
111. Tobon GJ, Canas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol 2007;26:578-81.
112. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008;43:397-401.
113. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5.
114. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
115. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
116. Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn's disease. BioDrugs 2007;21:125-32.
117. Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lym-phomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013;108:99-105.
118. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30.
119. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
120. De Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101.
121. Dubinsky MC. Monitoring of AZA/6-MP treatment in children with IBD is necessary. Inflamm Bowel Dis 2003;9:386-8.
122. Kim MJ, Choe YH. Monitoring and safety of azathioprine therapy in inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr 2013;16:65-70.
123. Boyer DL, Li BU, Fyda JN, et al. Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1989;8:528-32.
124. Besnard M, Debray D, Durand P, et al. Sulfasalazine-induced fulminant hepatitis in pediatric Crohn's disease: report of two cases. J Pediatr Gastroenterol Nutr 1998;26:119-20.
125. Marinos G, Riley J, Painter DM, et al. Sulfasalazine-induced fulminant hepatic failure. J Clin Gastroenterol 1992;14:132-5.
126. Ribe J, Benkov KJ, Thung SN, et al. Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine. Am J Gastroenterol 1986;81:205-8.
127. Rubin R. Sulfasalazine-induced fulminant hepatic failure and necro-tizing pancreatitis. Am J Gastroenterol 1994;89:789-91.
128. Namias A, Bhalotra R, Donowitz M. Reversible sulfasalazine-induced granulomatous hepatitis. J Clin Gastroenterol 1981;3:193-8.
129. Braun M, Fraser GM, Kunin M, et al. Mesalamine-induced granulo-matous hepatitis. Am J Gastroenterol 1999;94:1973-4.
130. De Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007;102:2747-53.
131. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercap-topurine or azathioprine. Inflamm Bowel Dis 2006;12:251-7.
132. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456-9.
133. De Graaf P, De Boer NK, Wong DR, et al. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br J Pharmacol 2010;160:1083-91.
134. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656-76.
135. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004;2:107-12.
136. Maggiore G, Caprai S. The liver in celiac disease. J Pediatr Gastro-enterol Nutr 2003;37:117-9.
137. Volta U, De Franceschi L, Lari F, et al. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998;352:26-9.
138. Lindgren S, Sjoberg K, Eriksson S. Unsuspected coeliac disease in chronic 'cryptogenic' liver disease. Scand J Gastroenterol 1994;29:661-4.
139. Sainsbury A, Sanders DS, Ford AC. Meta-analysis: coeliac disease and hypertransaminasaemia. Aliment Pharmacol Ther 2011;34:33-40.
140. Farre C, Esteve M, Curcoy A, et al. Hypertransaminasemia in pediatric celiac disease patients and its prevalence as a diagnostic clue. Am J Gastroenterol 2002;97:3176-81.
141. Bardella MT, Fraquelli M, Quatrini M, et al. Prevalence of hyper-transaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology 1995;22:833-6.
142. Vajro P, Fontanella A, Mayer M, et al. Elevated serum aminotransfer-ase activity as an early manifestation of gluten-sensitive enteropathy. J Pediatr 1993;122:416-9.
143. Bonamico M, Pitzalis G, Culasso F, et al. Hepatic damage in celiac disease in children. Minerva Pediatr 1986;38:959-62.
144. Jacobsen MB, Fausa O, Elgjo K, et al. Hepatic lesions in adult coeliac disease. Scand J Gastroenterol 1990;25:656-62.
145. Volta U. Pathogenesis and clinical significance of liver injury in celiac disease. Clin Rev Allergy Immunol 2009;36:62-70.
146. Hagander B, Berg NO, Brandt L, et al. Hepatic injury in adult coeliac disease. Lancet 1977;2:270-2.
147. Novacek G, Miehsler W, Wrba F, et al. Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. Eur J Gas-troenterol Hepatol 1999;11:283-8.
148. Freeman HJ. Hepatic manifestations of celiac disease. Clin Exp Gastroenterol 2010;3:33-9.
149. Bizzaro N, Villalta D, Tonutti E, et al. IgA and IgG tissue transglu-taminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis. Dig Dis Sci 2003;48:2360-5.
150. Volta U, Rodrigo L, Granito A, et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol 2002;97:2609-13.
151. Kingham JG, Parker DR. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 1998;42:120-2.
152. Mirzaagha F, Azali SH, Islami F, et al. Coeliac disease in autoimmune liver disease: a cross-sectional study and asystematic review. Dig Liver Dis 2010;42:620-3.
153. Schrumpf E, Abdelnoor M, Fausa O, et al. Risk factors in primary sclerosing cholangitis. J Hepatol 1994;21:1061-6.
154. Caprai S, Vajro P, Ventura A, et al. Autoimmune liver disease associated with celiac disease in childhood: a multicenter study. Clin Gastroenterol Hepatol 2008;6:803-6.
155. Diamanti A, Basso MS, Pietrobattista A, et al. Prevalence of celiac disease in children with autoimmune hepatitis. Dig Liver Dis 2008;40:965.
156. El-Shabrawi M, El-Karaksy H, Mohsen N, et al. Celiac disease in children and adolescents with autoimmune hepatitis: a single-centre experience. J Trop Pediatr 2011;57:104-8.
157. Tosun MS, Ertekin V, Selimoglu MA. Autoimmune hepatitis associated with celiac disease in childhood. Eur J Gastroenterol Hepatol 2010;22:898-9.
158. Bridoux-Henno L, Dabadie A, Briard D, et al. A case of celiac disease presenting with autoimmune hepatitis and erythroblastopenia. J Pediatr Gastroenterol Nutr 2001;33:616-9.
159. Kaukinen K, Halme L, Collin P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002;122:881-8.
160. Lacaille F, Canioni D, Bernard O, et al. Celiac disease, inflammatory colitis, and primary sclerosing cholangitis in a girl with Turner's syndrome. J Pediatr Gastroenterol Nutr 1995;21:463-7.
161. Gogos CA, Nikolopoulou V, Zolota V, et al. Autoimmune cholangitis in a patient with celiac disease: a case report and review of the literature. J Hepatol 1999;30:321-4.
162. Rubio-Tapia A, Murray JA. Liver involvement in celiac disease. Minerva Med 2008;99:595-604.
163. Rubio-Tapia A, Murray JA. Celiac disease beyond the gut. Clin Gastroenterol Hepatol 2008;6:722-3.
164. Casswall TH, Papadogiannakis N, Ghazi S, et al. Severe liver damage associated with celiac disease: findings in six toddler-aged girls. Eur J Gastroenterol Hepatol 2009;21:452-9.
165. Panetta F, Nobili V, Sartorelli MR, et al. Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management. Pediatr Drugs 2012;14:35-41.
166. Husby S, Koletzko S, Korponay-Szabo IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136-60.
167. Stevens FM, McLoughlin RM. Is coeliac disease a potentially treatable cause of liver failure? Eur J Gastroenterol Hepatol 2005;17:1015-7.
168. Lindberg J, Ahren C, Jonsson J. Gluten-free diet in chronic active hepatitis associated with intestinal villous atrophy. Hepatogastroen-terology 1982;29:52-4.
169. Mounajjed T, Oxentenko A, Shmidt E, et al. The liver in celiac disease: clinical manifestations, histologic features, and response to gluten-free diet in 30 patients. Am J Clin Pathol 2011;136:128-37.
170. Colecchia A, Di Biase AR, Scaioli E, et al. Coeliac disease and autoimmune hepatitis: gluten-free diet can influence liver disease outcome. Dig Liver Dis 2011;43:247.
171. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001.
172. Debray D, Kelly D, Houwen R, et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011;10:S29-36.
173. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002;36:1374-82.
174. Mayer-Hamblett N, Kloster M, Ramsey BW, et al. Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials. Contemp Clin Trials 2013;34:232-8.
175. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999;30:1151-8.
176. Lamireau T, Monnereau S, Martin S, Etal. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 2004;41:920-5.
177. Colombo C. Hepatobiliary disease in cystic fibrosis. In: Kelly D, ed. Disease of the Liver and Biliary System in Children. Oxford: Wiley-Blackwell; 2008:270-88.
178. Colombo C, Russo MC, Zazzeron L, et al. Liver disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 2006;43:S49-55.
179. Debray D, Lykavieris P, Gauthier F, et al. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol 1999;31:77-83.
180. Efrati O, Barak A, Modan-Moses D, et al. Liver cirrhosis and portal hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol 2003;15:1073-8.
181. Gooding I, Dondos V, Gyi KM, et al. Variceal hemorrhage and cystic fibrosis: outcomes and implications for liver transplantation. Liver Transpl 2005;11:1522-6.
182. Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 2004;6:231-9.
183. Colombo C, Apostolo MG, Ferrari M, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994;124:393-9.
184. Wilschanski M, Rivlin J, Cohen S, et al. Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics 1999;103:52-7.
185. Fustik S, Trajkovska M, Jakovska T, et al. Screening for liver disease in cystic fibrosis: analysis of clinical and genetic risk factors for its development. Turk J Pediatr 2008;50:526-32.
186. Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009;302:1076-83.
187. De Haan W. A marker associated with increased risk for severe liver disease in cystic fibrosis. Clin Genet 2010;77:434-5.
188. Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol 2010;24:585-92.
189. Nagel RA, Westaby D, Javaid A, et al. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 1989;2:1422-5.
190. Strandvik B, Hjelte L, Gabrielsson N, et al. Sclerosing cholangitis in cystic fibrosis. Scand J Gastroenterol Suppl 1988;143:121-4.
191. Durieu I, Pellet O, Simonot L, et al. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol 1999;30:1052-6.
192. Smith JL, Lewindon PJ, Hoskins AC, et al. Endogenous ursodeoxy-cholic acid and cholic acid in liver disease due to cystic fibrosis. Hepatology 2004;39:1673-82.
193. Colombo C, Battezzati PM, Podda M, et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-mind multicenter trial. Hepatology 1996;23:1484-90.
194. Colombo C, Castellani MR, Crosignani A, et al. Abnormalities in biliary drainage may predict a better response to ursodeoxycholic acid in cystic fibrosis-associated liver disease. Hepatology 1996;24:298-398.
195. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepato-logy 1998;27:166-74.
196. Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2000;2: CD000222.
197. Colombo C, Battezzati PM, Crosignani A, et al. Effects of taurine and ursodeoxycholic acid on liver function tests in patients with cystic fibrosis. Acta Univ Carol [Med] (Praha) 1990;36:148-51.
198. Van De Meeberg PC, Houwen RH, Sinaasappel M, et al. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related chole-static liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol 1997;32:369-73.
199. Siano M, De Gregorio F, Boggia B, et al. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease. Dig Liver Dis 2010;42:428-31.
200. Melzi ML, Kelly DA, Colombo C, et al. Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transpl Int 2006;19:726-31.
201. Noble-Jamieson G, Barnes N, Jamieson N, et al. Liver transplantation for hepatic cirrhosis in cystic fibrosis. J R Soc Med 1996;89(suppl 27):31-7.
202. Fridell JA, Bond GJ, Mazariegos GV, et al. Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center's experience. J Pediatr Surg 2003;38:1152-6.
203. Molmenti EP, Squires RH, Nagata D, et al. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant 2003;7:93-7.
204. Hansen K, Horslen S. Metabolic liver disease in children. Liver Transpl 2008;14:713-33.
205. Couetil JP, Soubrane O, Houssin DP, et al. Combined heart-lung-liver, double lung-liver, and isolated liver transplantation for cystic fibrosis in children. Transpl Int 1997;10:33-9.
206. Grannas G, Neipp M, Hoeper MM, et al. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation 2008;85:524-31.